The cases of Gleevec and Humira generics illustrate how the incentives within the supply chain for specialty drugs can keep generic and biosimilar prices higher than a “true” generic should be. Humira’s “patent thicket” is one method of what is often called “patent gaming,” or dissuading competition through frivolous patents (which should be eliminated). But there are other reasons that a drug’s price might not fall very much when it goes off patent. Let’s take a look…